Weight-Loss Drug Misuse Under Scanner, Centre Warns Of Legal Action For Violations

The Centre has intensified its crackdown on the misuse and unauthorised sale of popular weight-loss and diabetes drugs, amid growing concerns over their easy availability across online platforms, pharmacies, and wellness clinics, triggering fears of unsupervised use and serious health risks.

The Drug Controller General of India (DCGI), along with State Drug Controllers, has carried out inspections across the country, auditing 49 businesses including online pharmacy warehouses, wholesalers, retailers and weight-loss clinics. Notices have been issued for violations, with officials warning that "non-compliance will result in licence cancellation, fines, and legal action."

The crackdown comes at a time when GLP-1 drugs, widely used for weight loss and diabetes, are seeing a surge in demand, but are increasingly being accessed without proper prescriptions through retail and digital channels. Authorities have flagged concerns over "on-demand availability" and potential misuse, prompting stricter surveillance.

Also Read: Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment

Adding to the concern is the growing availability of generic versions of these drugs, which has made them more accessible and, in some cases, cheaper. While this improves affordability, it has also raised regulatory red flags over quality control, indiscriminate use, and the risk of these medicines being sold without proper prescriptions or medical oversight, further fuelling the current crackdown.

Reiterating the rules, the government has stressed that these drugs "cannot be purchased over the counter" and can only be prescribed by specialists such as endocrinologists, internal medicine experts, and cardiologists.

To curb misleading promotion, a March 10, 2026, advisory directed manufacturers to stop advertisements that encourage non-prescription use.

GLP-1 (glucagon-like peptide-1 receptor agonist) drugs are considered a breakthrough in treating type 2 diabetes and obesity, working by stimulating insulin release, suppressing excess glucagon, and slowing gastric emptying, thereby controlling blood sugar, and reducing appetite.

However, the government has issued a strong caution, noting that these medicines "carry serious side effects and must only be taken under the supervision of a qualified medical specialist."

Side effects range from nausea and dizziness to more severe complications such as pancreatitis, kidney injury, bowel obstruction, and even thyroid cancer, raising concerns over unsupervised consumption.

Also Read: GLP-1 Drugs And Muscle Loss: Doctor Warns Of Hidden Side Effects Of Weight Loss Drugs

The government has warned of strict penal action against any violations in the sale and promotion of GLP-1 drugs. Officials have underlined the seriousness of enforcement, stating that instances of unauthorised sale, improper prescription practices, or misleading advertising "will result in licence cancellation, fines, and legal action".

The rising popularity of drugs such as semaglutide, liraglutide and tirzepatide has added to the urgency, as India simultaneously faces a growing burden of obesity and type 2 diabetes, both major drivers of cardiovascular disease and other non-communicable illnesses.

Health experts underline that while these drugs can aid treatment, lifestyle changes remain critical, including maintaining a healthy weight, regular physical activity, and a balanced diet.

With stricter inspections set to continue, authorities have urged the public to exercise caution and ensure that GLP-1 drugs are used only under medical supervision and sourced through regulated channels.

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.